Douglas Carr
Senior VP of Finance & Operations, Principal Financial Officer and SecretaryMr. Douglas Carr, C.P.A., also known as Doug, serves as Principal Financial Officer at Century Therapeutics, Inc since August 2025. He served as Interim Principal Financial Officer at Century Therapeutics, Inc since July 11, 2025 until August 2025 and served as its Senior Vice President of Finance and Operations since May 2023 until July 11, 2025 and serves as Secretary and also served as its Vice President of Finance until May 2023. He served as Interim Principal Financial Officer at Century Therapeutics, Inc since February 2, 2024. He was VP of Finance at Novira Therapeutics, Inc., where he directed all financial and fiscal management aspects of the operations and played a key role in the sale of the Company to J&J in December 2015. Mr. Carr previously served as the Financial Controller at Omthera Pharmaceuticals, Inc. Mr. Carr has broad-based finance experience supporting US and international business operations. Prior to joining Omthera in November 2009, he served as Controller - Pediatric Vaccines Franchise for Merck & Co., Inc. He directed the financial planning and reporting processes and provided decision-support analysis on projects and initiatives. Mr. Carr was also Business Director for the Zocor franchise where he was responsible for day-to-day operations management of the ZOCOR Franchise including forecasting, reporting, budget management and product/sample supply. He currently serves on the Board of Directors at Heritage Conservancy in Doylestown, Pennsylvania. Mr. Carr is licensed as a Certified Public Accountant in New Jersey and he received his B.A. degree in Accounting from Rutger's University.
Positions
- Company NameCentury Therapeutics, Inc.Stock CodeIPSCPositionSenior VP of Finance & Operations, Principal Financial Officer and SecretaryColleagues
- BPBrent PfeiffenbergerPresident, CEO & Chairman
- GRGregory RussottiChief Technology & Manufacturing Officer
- CAChad A. CowanChief Scientific Officer
- KKKrista KauppinenVP, General Counsel & Head of Intellectual Property
- KLKimberly Lynn BlackwellLead Independent Director
- DEDaphne E. QuimiIndependent Director
- MPMartin Patrick MurphyIndependent Director
- JJJoseph JimenezSpecial Advisor to the Board
